Marisa Wexler MS,  —

The Axial Spondyloarthritis International Foundation (ASIF) is encouraging members of the ankylosing spondylitis community to wear orange shoelaces as part of this Saturday’s “Lace Up for axSpA” annual World AS Day. Held each year on the first Saturday of May, the event is designed  to raise awareness…

The U.S. Food and Drug Administration (FDA) has agreed to review an application seeking approval of AVT05, a proposed biosimilar for Simponi (golimumab), which is an approved treatment for ankylosing spondylitis. Developers Alvotech and Teva Pharmaceuticals said this marks the first time that the FDA has…

One year of treatment with Rinvoq (upadacitinib) reduced disease activity for most adults with non-radiographic axial spondyloarthritis (nr-axSpA) — an inflammatory condition related to ankylosing spondylitis (AS) — in a Phase 3 clinical trial. “These longer-term results continue to support the favorable benefit-risk profile of [Rinvoq] once daily…

Machine learning and deep learning are already showing promise as tools to help diagnose and manage ankylosing spondylitis (AS), though the field is still in its infancy and more work must be done, a new review paper highlights. The paper, “Machine Learning and Deep Learning for…

Up to five years of treatment with bimekizumab safely leads to sustained reductions in symptoms and disease activity, as well as improvements in physical function and life quality, for people with ankylosing spondylitis (AS). That’s according to new data from the now-completed Phase 2b BE AGILE clinical…

People with ankylosing spondylitis (AS) who carry a mutation in the gene that encodes the CARD9 protein may be more likely to respond to treatments that block an inflammatory signaling molecule known as interleukin-17 (IL-17), a preclinical study suggests. Scientists found that the protein CARD9 is involved in…

A form of exercise using a device that mimics horseback riding may be an effective intervention to boost muscle strength, limit disease severity, and improve life quality for people with ankylosing spondylitis (AS), according to a new study. The novel approach tested in the trial uses a device called…

Treatment with Rinvoq (upadacitinib) substantially reduced disease activity for most adults with ankylosing spondylitis (AS) who had failed to respond to other treatments, according to one-year data from a clinical trial. “These 1-year data demonstrated consistent improvement and maintenance of response with [Rinvoq] treatment in treatment-refractory patients…

More than a dozen genes related to inflammatory cell death were found to be expressed at atypical levels in ankylosing spondylitis (AS) patients in a new study, suggesting these genes could be used to help diagnose the disease. The analyses also identified three small molecules that may help to…

Seven genes — from a pool of four dozen identified as being different in people with ankylosing spondylitis (AS) — may be potential genetic biomarkers for this rare type of arthritis, according to a new study done based on computer analyses. The study also uncovered several molecules that may…